Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug–Drug Interaction Studies

por Elmeliegy, Mohamed, Vourvahis, Manoli, Guo, Cen, Wang, Diane D.
Publicado 2020

Discordance Between Child‐Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology Compounds

por Elmeliegy, Mohamed, Yang, Derek Z., Salama, Engie, Parivar, Kourosh, Wang, Diane D.
Publicado 2020

Analysis of US Food and Drug Administration Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing Recommendations

por Yang, Derek Z., Alhadab, Ali, Parivar, Kourosh, Wang, Diane D., Elmeliegy, Mohamed
Publicado 2021

Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib

por Zheng, Jenny, Yu, Yanke, Durairaj, Chandrasekar, Diéras, Véronique, Finn, Richard S., Wang, Diane D.
Publicado 2020

The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors

por Durairaj, Chandrasekar, Chakrabarti, Jayeta, Ferrario, Cristiano, Hirte, Holger W., Babu, Sunil, Piha-Paul, Sarina A., Plotka, Anna, Hoffman, Justin, Shi, Haihong, Wang, Diane D.
Publicado 2021

Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment

por Guo, Cen, Yu, Yanke, Chakrabarti, Jayeta, Piha‐Paul, Sarina A., Moroose, Rebecca, Plotka, Anna, Shi, Haihong, Durairaj, Chandrasekar, Wang, Diane D., Wainberg, Zev A.
Publicado 2022

Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer

por Durairaj, Chandrasekar, Ruiz-Garcia, Ana, Gauthier, Eric R., Huang, Xin, Lu, Dongrui R., Hoffman, Justin T., Finn, Richard S., Joy, Anil A., Ettl, Johannes, Rugo, Hope S., Zheng, Jenny, Wilner, Keith D., Wang, Diane D.
Publicado 2018